Nuwellis, Inc. (NUWE) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Nuwellis, Inc. is a medical technology company focused on commercializing the Aquadex SmartFlow system for ultrafiltration therapy to treat fluid overload in adult and pediatric patients. The company operates as a single segment and is headquartered in Eden Prairie, Minnesota.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Sales | $1.73 million | $2.19 million | $3.63 million | $4.05 million |
| Gross Profit | $0.96 million | $1.47 million | $2.03 million | $2.67 million |
| Gross Margin | 55.5% | 67.2% | 55.8% | 65.8% |
| Net Loss | $(12.55) million | $(7.73) million | $(15.57) million | $(12.06) million |
| Cash and Equivalents | $4.45 million (as of June 30, 2025) | |||
| Warrant Liabilities | $14.07 million (as of June 30, 2025) | |||
| Stockholders' Equity (Deficit) | $(8.96) million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 21.4% in Q2 and 10.4% YTD compared to 2024. The decline was driven by a temporary backorder of approximately $400,000 in circuit revenue due to an industry-wide sterilization vendor issue, alongside decreases in console sales.
- Margin Compression: Gross margins contracted from 67.2% to 55.5% in Q2 due to unfavorable manufacturing variances and under-absorption of fixed overhead caused by lower production volumes.
- Significant Financing Expense: Net loss widened significantly due to a $10.55 million financing expense in Q2. This resulted from a June 2025 public offering where the fair value of issued warrants ($14.5 million) exceeded gross proceeds ($5.0 million), creating a "Day 1 interest" charge.
- Capital Structure: The company executed a 1-for-42 reverse stock split effective July 3, 2025. Outstanding common shares increased to 527,158 (split-adjusted) from 104,142 at year-end 2024 due to the offering and conversions.
Outlook, Risks, and Unusual Items
- Going Concern: The filing states substantial doubt about the company's ability to continue as a going concern for at least 12 months due to an accumulated deficit of $314.4 million and recurring operating losses. Management believes current resources will support operations into Q4 2025 but additional capital will be required.
- Nasdaq Compliance: The company faced delisting risks regarding minimum stockholders' equity and bid price requirements. Following the reverse stock split and warrant reclassifications, the company reports pro forma stockholders' equity of $4.51 million, believing it is now compliant with Nasdaq rules.
- Strategic Shifts:
- Terminated the REVERSE-HF clinical trial in July 2025 to save approximately $4.0 million over 2.5 years.
- Announced an exit from international operations in August 2025 to focus exclusively on the U.S. market.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, citing two material weaknesses in financial reporting controls.
Investor Verification Checklist
- Verify the status of the sterilization vendor backorder and its impact on Q3 2025 revenue recovery.
- Confirm the final classification of Series A and Series B warrants on the balance sheet following the reverse stock split and subsequent exercises.
- Monitor the company's ability to raise additional capital before Q4 2025 to address the going concern warning.
- Review the remediation plan for the identified material weaknesses in internal controls over financial reporting.
- Assess the financial impact of exiting international operations and terminating the REVERSE-HF trial on future operating expenses.